Total IgE is a nonspecific marker of atopy, not a diagnostic test for allergy. A single elevated level doesn’t tell you which substances, if any, a patient is allergic to. The best next step is to perform antigen-specific testing (such as specific IgE tests or skin prick testing) to identify which allergens the patient may be sensitized to and to correlate these findings with the patient’s clinical history. Therefore, antigen-specific testing should be done. The other conclusions aren’t supported by a total IgE value alone: a raised total IgE does not guarantee allergic reactions, it does not by itself indicate a risk of anaphylaxis, and it does not prove that the patient has allergic tendencies—it simply raises the possibility and warrants targeted testing to confirm sensitizations.

Transplant types are defined by the donor–recipient relationship and species. A kidney donated from one person to another of the same species but who is not genetically identical is an allograft. Here, the donor is a man and the recipient is his sister—two different individuals of the same species—so the graft fits the allograft category. An autograft would be tissue moved within the same person, an isograft would be between identical twins, and a xenograft would be from another species.

Direct quantification of a soluble cytokine in a sample requires an assay that specifically detects the molecule. ELISA uses antibodies that bind the target cytokine and produce a measurable signal proportional to its concentration, giving precise, quantitative results in fluids or culture supernatants. This specificity and sensitivity make it ideal for measuring a single cytokine. The other approaches assess cellular responses rather than the cytokine’s actual amount: blast formation and T-cell proliferation look at how cells multiply in response to stimuli, not the cytokine’s level; measuring leukocyte chemotaxis examines movement toward signals, which again reflects activity rather than exact concentration.

After a positive HIV screening result, the test that best serves as confirmation is an assay that detects antibodies to both HIV-1 and HIV-2 and can distinguish between them. This aligns with the CDC’s current testing algorithm, which uses an HIV-1/HIV-2 antibody differentiation immunoassay to confirm infection and identify the specific virus type. If this differentiation test is reactive for either HIV-1 or HIV-2, a diagnosis is established. If the differentiation test is nonreactive or indeterminate after a reactive screen, a nucleic acid test measuring HIV RNA is used to resolve possible acute infection or discordant results. Western blot, once used for confirmation, is no longer recommended due to its limitations and potential for indeterminate results. HIV RNA testing has its place in certain scenarios, but it is not the standard confirmatory test immediately after a reactive antibody screening result unless the differentiation step is inconclusive.